The GMP certificate of Guizhou bailing and Rentang Pharmaceutical Co., Ltd. was withdrawn in violation of the drug production quality management specifications!

On March 17, Guizhou bailing Pharmaceutical Co., Ltd issued an announcement that its subordinate holding subsidiary, Guizhou bailing enterprise group and Rentang Pharmaceutical Co., Ltd (hereinafter referred to as "herntang Pharmaceutical Co., Ltd."), due to their violation of the provisions of the "drug production quality management specifications", in accordance with the provisions of Article 33 of the "measures for the administration of the certification of the" drug production quality management specifications ", Guizhou food and Drug Administration recalled herntang pharmaceutical according to law GMP of Tang Pharmaceutical Co., Ltd According to the 2018 performance express report of Guizhou bailing, the total operating income of the consolidated statements of Guizhou bailing in 2018 is 3139.0418 million yuan, and the net profit attributable to the shareholders of the listed company is 554.2554 million yuan In 2018, the total operating revenue of herrentang Pharmaceutical Co., Ltd was RMB 232.9407 million, with a net profit of RMB 27.055 million, accounting for 4.88% of the company's consolidated statements (the above data is only the preliminary accounting data, which has been audited by the internal audit department of the company and has not been audited by the accounting firm, and may be different from the final data disclosed in the annual report) The withdrawal of the GMP certificate of helintang pharmaceutical will not have a significant adverse impact on the company's current production and operation and financial situation in 2019 The specific losses caused by this incident are still under statistics and calculation The following is the original announcement: